Pharmacy Cost-Containment Strategies for Self-Funded Employers

The first place I would start is the PBM agreement.

PBM contracts are often complicated, and many employers are forced to rely on the PBM to explain whether the arrangement is working. In many ways, that is like asking a vendor to grade its own performance.

Employers need to understand whether the contract uses spread pricing or pass-through pricing, how rebates are handled, what fees are being charged, and whether the PBM receives additional compensation from manufacturers, pharmacies, or other sources.

Audit rights, access to claims data, and termination provisions also matter. A contract may include large discount guarantees and attractive rebate projections while still producing a higher overall cost.

That is why the goal should not be the largest rebate. The goal should be the lowest net cost after considering the drug price, rebates, fees, dispensing costs, clinical outcomes, and employee experience.

Employers should not wait until renewal to determine whether their pharmacy program is performing well.

A meaningful review should look beyond a standard report showing discounts and rebates. It should evaluate actual claims, utilization patterns, specialty spending, formulary decisions, and pricing at the individual drug level.

This type of review may uncover brand-name medications being used when lower-cost alternatives are available, specialty drugs being filled through unnecessarily expensive channels, low biosimilar utilization, or manufacturer assistance opportunities that are being missed.

It may also reveal that formulary decisions are being influenced more by rebate arrangements than by the true net cost of the medication.

Employers should understand every meaningful source of PBM compensation. Transparency should extend well beyond rebates.

Specialty medications may represent a small percentage of total prescriptions, but they can account for a very large share of total pharmacy spending.

These medications cannot be managed the same way as traditional retail prescriptions.

Employers should understand where the medication is being dispensed, whether it is billed through the pharmacy or medical benefit, whether a biosimilar is available, whether the dosage is appropriate, and whether manufacturer assistance or another sourcing option should be considered.

Site of care is also a major issue.

The same medication may cost substantially more when administered in a hospital outpatient department than it would in a physician’s office, infusion center, or home setting. In many cases, the difference has very little to do with the medication itself and a lot to do with where the care is delivered.

Employers also need to review drugs billed through the medical plan using J-codes and Q-codes. Some of the highest-cost medications will never appear on a traditional PBM report.

A pharmacy strategy is incomplete if it only looks at prescription claims.

Most employers assume the formulary is based entirely on clinical effectiveness. That is not always the case.

Rebates and manufacturer agreements can influence which medications are preferred, excluded, or placed on a certain tier. A medication with a large rebate may look attractive on paper while still producing a higher net cost to the plan.

A well-designed formulary should balance clinical quality, employee access, and total net cost.

That may involve generic substitution, biosimilar adoption, prior authorization, step therapy, quantity limits, and dose optimization. It may also involve removing low-value medications when there are clinically appropriate alternatives available.

These programs should not be designed simply to deny claims. They should help employees access the right treatment while protecting the plan from waste and unnecessary spending.

Poorly designed utilization management creates delays, frustration, and confusion. Well-designed programs combine clinical oversight with strong employee support.

GLP-1 medications have become one of the biggest benefit strategy questions facing employers.

These drugs can produce meaningful clinical results, but they can also create significant long-term cost when coverage is added without clear rules or ongoing management.

I do not believe GLP-1 coverage should be treated as a simple yes-or-no decision.

Employers should think about clinical eligibility, prior authorization, ongoing monitoring, participation in a structured weight-management program, and continued coverage based on measurable results.

It may also make sense to separate coverage decisions for diabetes treatment from coverage for weight loss.

Simply increasing the employee copay does not solve the underlying problem. It may only make the medication unaffordable for employees while doing nothing to improve the price the plan is paying.

The better approach is to create responsible access, establish clear expectations, and determine whether the program is financially sustainable over time.

Manufacturer assistance and alternative funding programs can create meaningful savings, particularly for certain specialty medications.

They can also create serious problems when they are not implemented correctly.

Before moving forward, employers should understand who qualifies for assistance, how the program affects deductibles and out-of-pocket limits, whether the plan document supports the arrangement, and how the TPA, PBM, and stop-loss carrier will treat the claim.

Employers also need to know what happens if an employee loses eligibility for assistance or if a manufacturer changes its program.

A savings projection may look impressive, but it does not mean much if an employee cannot access medication or the claim becomes ineligible under the stop-loss contract.

These programs need to be coordinated carefully and supported by a strong advocacy team.

A pharmacy strategy should include more than PBM data.

Many expensive medications are billed through the medical plan, including oncology treatments, infusion therapies, and other physician-administered drugs.

Employers should review medical claims for J-code and Q-code medications, hospital outpatient drug administration, provider markups, duplicate billing, and the location where the medication is being administered.

In many cases, the cost of the facility is just as important as the cost of the drug.

Site-of-care management, specialized clinical review, centers of excellence, and direct contracting may create meaningful savings without changing the underlying treatment.

That is an important distinction. The goal is not to change the care an employee needs. It is to make sure the plan is not dramatically overpaying for the same care.

Before implementing any major pharmacy savings strategy, employers need to understand how it will affect stop-loss coverage.

A program may reduce the plan’s immediate cost but create additional financial risk if the claim is no longer eligible for reimbursement.

Employers should confirm whether the claim remains covered, whether the expense accumulates toward the specific deductible, how manufacturer payments are treated, and whether alternative sourcing or funding arrangements are excluded.

The plan document and stop-loss contract also need to align.

The advisor, PBM, TPA, stop-loss carrier, legal counsel, and clinical vendors should all be on the same page before major changes are made.

This is an area where a good idea can become an expensive mistake when the details are not worked through in advance.

Pharmacy cost containment is not just a contract or claims issue. It is also an employee experience issue.

Employees may not understand why a medication was denied, why their pharmacy changed, whether a biosimilar is available, or how to apply for manufacturer assistance.

They should not be left to work through those issues on their own.

A strong advocacy program can help employees navigate prior authorization, resolve denied claims, compare pharmacy options, communicate with their physician, transition to a lower-cost alternative, and avoid interruptions in treatment.

These programs work much better when employees receive personal support instead of a generic denial letter and an 800 number.

The employer may be focused on controlling cost, but the employee is focused on getting the medication they need. A successful strategy has to address both.

Employers should be careful about evaluating pharmacy performance based only on discounts, rebates, or generic dispensing rates.

Those numbers can be useful, but they do not tell the whole story.

A better review should include gross and net pharmacy cost, specialty drug spending, drugs billed through the medical plan, biosimilar utilization, manufacturer assistance, site-of-care savings, year-over-year trend, employee disruption, and clinical outcomes.

The least expensive medication is not always the right option. At the same time, the most expensive medication is not always clinically better.

The goal is not simply to reduce utilization. The goal is to improve value.

Self-funded employers cannot afford to treat the pharmacy benefit as a set-it-and-forget-it arrangement.

The market is changing too quickly, the financial incentives are too complicated, and the potential exposure is too large.

The employers that achieve the best results are not necessarily the ones with the largest rebate guarantee. They are the ones that understand where every pharmacy dollar goes, ask better questions, challenge misaligned incentives, and actively manage the program throughout the year.

Self-funding gives employers more control over their pharmacy strategy.

The key is being willing to use it.